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Dissecting the role of H3K27 acetylation
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The Polycomb repressive complexes PRC1 and PRC2 act non-redundantly at target genes
to maintain transcriptional programs and ensure cellular identity. PRC2 methylates lysine
27 on histone H3 (H3K27me), while PRC1 mono-ubiquitinates histone H2A at lysine 119
(H2Aub1). Here we present engineered mouse embryonic stem cells (ESCs) targeting the
PRC2 subunits EZH1 and EZH2 to discriminate between contributions of distinct H3K27
methylation states and the presence of PRC2/1 at chromatin. We generate catalytically
inactive EZH2 mutant ESCs, demonstrating that H3K27 methylation, but not recruitment
to the chromatin, is essential for proper ESC differentiation. We further show that EZH1
activity is sufﬁcient to maintain repression of Polycomb targets by depositing H3K27me2/3
and preserving PRC1 recruitment. This occurs in the presence of altered H3K27me1
deposition at actively transcribed genes and by a diffused hyperacetylation of chromatin
that compromises ESC developmental potential. Overall, this work provides insights for the
contribution of diffuse chromatin invasion by acetyltransferases in PRC2-dependent loss
of developmental control.
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The proper establishment and regulation of transcriptionalprograms is of fundamental importance during develop-ment. Polycomb group (PcG) proteins act as epigenetic
regulators that ensure the maintenance of cell-speciﬁc transcrip-
tional programs by exerting a crucial role during establishment
of cellular identity and cell fate transitions. This is guaranteed
by the activity of two major PcG repressive complexes (PRCs),
PRC1 and PRC2, that act non-redundantly at the same target
genes to ensure proper gene repression via post-translational
modiﬁcations of histone proteins1. The importance of PRCs
is highlighted by the early embryonic lethality of knockout
mice2–5, as well as the failure to establish proper in vitro differ-
entiation of embryonic stem cells (ESCs) lacking core PRC1 and
PRC2 subunits6–9. PRCs maintain a critical role also in adult
life, with both PRC1 and PRC2 activities playing speciﬁc roles in
controlling cell identity and tissue homeostasis1. Importantly,
these same activities are also frequently deregulated in different
type of human tumors by genetic lesions that preferentially target
PRC2 activity1. Such mutations can result in either gain- or loss-
of-function of PRC2, depending on the tissue and the environ-
mental context8,10–15.
PRC1 is responsible for the deposition of histone H2A lysine
119 mono-ubiquitination (H2Aub1), catalyzed by activity of its
redundant E3-ligase subunits RING1A or RING1B16. PRC2
activity relies on the methyltransferases EZH1 and EZH2, which
deposit all three methylation states of lysine 27 onto histone
H3 (H3K27me)17–19. EZH1 and EZH2 are mutually exclusive
within PRC2 and retain distinct enzymatic proprieties in vitro,
with EZH2 showing higher methyltransferase efﬁciency under the
same reaction conditions19. While loss of EZH1 is dispensable
for embryogenesis and mice viability20, EZH1 fails to compensate
EZH2 loss of function that results in early embryonic lethality
during gastrulation2. Both EZH1 and EZH2 are expressed in
mouse ESCs and are found associated within PRC23,18. PRC2-
EZH1 and PRC2-EZH2 complexes are associated to a set of
ancillary proteins that are not required for intrinsic PRC2 enzy-
matic activity but play distinct roles in regulating chromatin
recruitment and activity21–26.
The mechanisms by which PRC1 and PRC2 complexes are
recruited to, and stabilized at, chromatin still remain points of
discussion. In Drosophila, recruitment occurs via Polycomb
response elements (PRE), which are distal cis-regulatory elements
about a few hundred base pairs long that are devoid of nucleo-
somes27. The recruitment mechanisms in mammals appear
to be divergent and are still not clear. CpG islands attract PRC1
and PRC2 complexes, and several subunits, such JARID2 and
Polycomb-like proteins (e.g., PHF1, MTF2, and PHF19), have
direct binding afﬁnities to these DNA motifs28,29; how speciﬁcity
is acquired, however, remains an open issue. PRC2 has been
proposed to be actively excluded from CpG islands (CpGi) by
RNA polymerase II activity, which would imply that PRC2 has
the potential ability to bind CpGs by default30. In this scenario,
neither the role that H2Aub1 exerts in vivo on PRC2 recruitment,
nor the role that PRC2 exerts on PRC1 recruitment, is clearly
deﬁned.
Multiple PRC1 subcomplexes with distinct biochemical pro-
prieties have been demonstrated to exist. These complexes are
commonly referred to as canonical or non-canonical, based on
their dependence on H3K27me3 for recruitment to target loci31.
It was also shown that PRC2 retains the ability to bind H2Aub1,
suggesting that deposition of H2Aub1 can control PRC2
recruitment and/or stabilization at target loci32–34. Studies in
Drosophila melanogaster have elegantly shown that preventing
H2Aub1 deposition by mutating K117, K118, K121, and K122 of
histone H2A, or by expressing a dRING catalytically inactive
mutant, did not result in homeotic transformations35. Similarly,
inactivating point mutations of RING1B in mice postpones
embryonic lethality from embryonic day E10.5 to E15.536.
Although RING1A was still expressed in these mice, these results
strongly suggest that lack of H2Aub1 deposition cannot pheno-
copy loss of PRC2 activity in vivo. Importantly, substituting
lysine for arginine in H3 (H3K27R) resulted in homeotic trans-
formations identical to E(z) loss-of-function in the developing
ﬂy embryos, pointing to H3K27me3 as the central hub for PcG
functions in ﬂy development37. Whether this also applies to
mammalian development remains to be addressed.
PRC2 activity controls all forms of H3K27 methylation17. We
have previously reported that while mono-methylated H3
(H3K27me1) is preferentially deposited at highly transcribed gene
bodies, tri-methylated H3 (H3K27me3) is deposited at promoter
regions concomitantly with PRC2 and PRC1 association17. Like
the CBX proteins of canonical PRC1, EED can bind H3K27me3
with its WD40 domain to stabilize PRC2 at its target sites and
to allosterically stimulate PRC2 enzymatic activity38. This also
generates an intrinsic biochemical competition for this mod-
iﬁcation between PRC1 and PRC2; binding of PRC2 reinforces
its activity at target sites but also serves as a docking site for
canonical PRC1.
In contrast, di-methylated H3 (H3K27me2) is a broadly dif-
fused modiﬁcation that, in ESCs, covers 70% of total H317.
Essentially, H3K27me2 “ﬁlls the gaps” between H3K27me1 and
H3K27me3 chromatin domains in intergenic and non-
transcribed intragenic genomic space. Importantly, we and oth-
ers have previously reported that global loss of H3K27 methyla-
tions results in an aberrant accumulation of H3K27 acetylation
mediated by CBP and p300 activity39,40. This occurs at all sites
in which H3K27 methylation is lost, including hyperacetylation
of PcG bound promoters and non-lineage-speciﬁc enhancer ele-
ments17. This observation raises the question of whether early
developmental failure in the absence of PRC2 activity is primarily
a consequence of loss of control of promoter repression due to
lack of H3K27me3 deposition, or a general failure caused by
diffuse chromatin hyperacetylation due to a lack of H3K27me2
deposition.
To address these questions, we generate a set of mutants to
entirely delete EZH1 and EZH2 proteins or completely inactivate
EZH2 catalytic activity without altering PRC2 assembly. We
now demonstrate that PRC2 is recruited to target sites indepen-
dently of H3K27me3 and H2Aub1 deposition. We further
show that the activity of EZH1 is sufﬁcient to deposit H3K27me3
at all PRC2 target sites but is unable to spread this modiﬁcation
to neighboring chromatin. Although this is sufﬁcient to fully
recruit PRC1 activity at these sites and to prevent hyperacetyla-
tion of all PcG target promoters, EZH1 activity is unable to
counteract diffused chromatin H3K27ac hyperacetylation caused
by H3K27me2 loss or to support proper ESC differentiation.
Together, these data strongly suggest that early developmental
failure induced by loss of PRC2 activity is a consequence of
chromatin H3K27 hyperacetylation rather than speciﬁc loss of
repressive control at target genes.
Results
Generation of EZH1/2 full KO and catalytically inactive ESC.
In order to dissect the role of H3K27 methylation from the
assembly and recruitment of the PRC2 complex to chromatin, we
generated a set of isogenic ESC lines carrying different mutations
by using CRISPR/Cas9 engineering to target the PRC2 complex.
Until now, EZH2-null ESC lines have used C-terminal deletions
to create functionally dead EZH2 protein by eliminating its cat-
alytic SET domain. However, this results in the expression of a
truncated protein that can still assemble into a normal PRC2
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complex18,41. To bypass this problem, we generated macrodele-
tions that eliminate the production of any polypeptide from the
Ezh2 gene (Ezh2 knockout [KO]). Following a similar strategy, we
have also generated a macro-deletion that targets independently
the Ezh2 paralog Ezh1 (Ezh1 KO). To further create double-KO
(dKO) ESCs, we sequentially targeted Ezh1 and Ezh2 with the
same gRNAs (Ezh1/2 dKO; Fig. 1a, Supplementary Fig. 1A, B, D,
and Supplementary Table 1). Consistent with previous reports,
ESCs lacking PRC2 activity proliferated as wild-type (WT), with
no changes in the expression of the pluripotency marker POU5F1
(OCT4; Fig. 1b). While loss of EZH1 was fully compensated
by EZH2 activity, Ezh2 KO displayed a global loss of both
H3K27me2 and H3K27me3 but retained normal H3K27me1
deposition. Consistent with this, all three H3K27 methylation
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forms were lost in Ezh1/2 dKOs (Fig. 1b). Overall, these data
show that: (i) all three forms of H3K27 methylation are under
EZH1 and EZH2 control in ESCs; (ii) H3K27me1 is fully com-
pensated by PRC2-EZH1; and (iii) loss of H3K27me2/me3 always
correlates with increased H3K27ac levels.
To further distinguish the role of the catalytic activity of PRC2
from that of its physical association at chromatin in living cells,
we screened several EZH2 mutations to determine how they
affected both roles. We found that the tyrosine-to-aspartic acid
substitution at amino acid 731 (Y731D) completely impaired
EZH2 catalytic activity. We thus generated physiological Ezh2
Y726D (equivalent to Y731D in human) homozygous mutations
in Ezh1 KO ESCs using CRISPR/Cas9 (termed Ezh2 Y726D;
Supplementary Fig. 1C, D). This led to complete loss of all three
H3K27 methylation states, to the same levels observed for Ezh1/2
dKO (Fig. 1b). It is important to highlight that, in contrast to
Ezh1/2 dKO ESCs, SUZ12 and EED were not destabilized in Ezh2
Y726D ESCs (Fig. 1b), and that they bound to the EZH2 Y726D
mutant with an identical efﬁciency as in WT ESCs (Fig. 1c).
Moreover, different PRC2 ancillary subunits: JARID2, MTF2,
PHF19 and EPOP, which specify distinct forms of PRC2, also
followed a similar expression behavior (Supplementary Fig. 2A).
Overall, these data show that EZH2 Y726D mutation leads to
PRC2 enzymatic loss-of-function without affecting protein
stability or PRC2 physiological complex assembly.
PRC2-EZH1 fails to spread H3K27me3 at PRC2 targets. To
further explore the effects of speciﬁc EZH1 and EZH2 loss-of-
function and PRC2 inactivation at a locus-speciﬁc level, we per-
formed H3K27me3 ChIP-seq analysis, with spiked Drosophila
chromatin reference for signal normalization, in the different
mutant ESC lines. Ezh1/2 dKO and Ezh2 Y726D ESCs displayed a
complete genome-wide loss of H3K27me3 deposition at PcG
bound sites deﬁned by association of PRC2 (SUZ12) or PRC1
(RING1B) in wild-type ESC (Supplementary Fig. 2B), further
underscoring that the EZH2 Y726D mutation is catalytically dead
(Fig. 1d). Importantly, while SUZ12 binding was displaced from
chromatin in Ezh1/2 dKO ESCs, its binding was retained in Ezh2
Y726D ESCs, demonstrating that speciﬁc PRC2 association to
target genes is independent from H3K27me3 deposition (Fig. 1d).
Although bulk levels of H3K27me3 seemed to be abolished in
Ezh2 KO ESCs analyzed by western blot (Fig. 1b), ChIP-seq
analysis revealed signiﬁcant H3K27me3 deposition at PRC2
bound sites as compared to Ezh1/2 dKOs or Ezh2 Y726D ESCs
(Fig. 1d, e). While SUZ12 levels were destabilized in the absence
of EZH2 (Fig. 1b), residual H3K27me3 deposition also correlated
with proper SUZ12 association at PRC2 sites in Ezh2 KO ESCs
(Fig. 1d, e and Supplementary Fig. 2C) displaying speciﬁc pro-
moter localization (Fig. 1d, e and Supplementary Fig. 2C, D).
Indeed, while nearly no H3K27me3 peaks were detected in Ezh1/
2 dKOs or Ezh2 Y726D ESCs, speciﬁc loss of EZH2 left intact
>70% of the H3K27me3-decorated sites detected in WT ESCs.
This is consistent with EZH1 being speciﬁcally recruited at the
same genomic sites in absence of EZH2 when re-expressed in
Ezh1/2 dKOs (Supplementary Fig. 3A–C). Importantly, MTF2,
JARID2, and PHF19 were also normally recruited at target pro-
moters in the absence of EZH2 (Supplementary Fig. 4A–C),
demonstrating that EZH1 can recruit both PRC2 forms to target
loci. Only the recruitment of EPOP was affected in the absence
of EZH2 (Supplementary Fig. 4D), suggesting a more speciﬁc
interaction with the PRC2-EZH2 complex. Genomic snapshots of
representative target loci conﬁrmed this result and further sug-
gested that, in the absence of EZH2, H3K27me3 deposition was
conﬁned within the borders of SUZ12 peaks, with no signs of
5′ or 3′ spreading present in WT cells (Fig. 1f). Although this
could be a consequence of a reduced occupancy and activity
(Fig. 1b, d), this result might also suggest that the PRC2-EZH1
complex is unable to spread the H3K27me3 mark outside the
area of physical PRC2 interaction with chromatin.
To gain further insight into this mechanism, we computed the
density of H3K27me3 deposition inside each SUZ12 peak or
within the neighboring regions (Supplementary Fig. 5A) selecting
a 1.2 kb region at both ends (Fig. 2a). This analysis showed that
H3K27me3 deposition is subjected to a larger intensity drop in
Ezh2 KO ESCs than in WT ESCs, suggesting a lack of
H3K27me3 spreading in Ezh2 KO ESCs (Fig. 2b). We therefore
quantiﬁed the amount of spreading in WT and Ezh2 KO ESC as
the ratio between the H3K27me3 density outside compared to
inside each SUZ12 peak at either the 5′ or 3′ end. Consistent with
the previous result, the spreading ratio was close to 1 at both ends
in WT ESCs but was signiﬁcantly reduced in Ezh2 KO ESCs,
demonstrating the failure to deposit H3K27me3 outside SUZ12
peak boundaries in these cells (Fig. 2c). Similar results were
obtained when the top 20% of bound sites or a larger 4 kb
window is taken into consideration in the analysis (Fig. 2d and
Supplementary Fig. 5B–D). Overall, these data show that PRC2-
EZH1 is recruited to PcG target loci, where it deposits H3K27me3
as normal but is impaired in consolidating H3K27me3 spreading
around the site of the PRC2 contact with chromatin. Importantly,
although H3K27me3 spreading was compromised in absence of
EZH2, EZH1 activity was sufﬁcient to preserve target genes
repression (Fig. 2e). While Ezh1/2 dKOs and Ezh2 Y726D ESC
showed preferential de-repression of a common set of direct
targets (Fig. 2e), these genes were maintained repressed in Ezh2
KO with very few expression changes (Fig. 2e and Supplementary
Fig. 5E).
De novo PRC2 recruitment is independent of H3K27me3 and
H2Aub1. To further explore the properties of PRC2 recruitment
to its target sites, and the role of H3K27me3 deposition in
determining the speciﬁcity of this recruitment, we cultured Ezh1/
2 dKO ESCs in the absence of any form of PRC2 and H3K27
methylation for several weeks. We then transiently reintroduced
the expression of a wild-type or Y731D mutant (equivalent to
Y726D in mouse) of human EZH2 for 24 h (Fig. 3a). This window
of expression was sufﬁcient to restore not only SUZ12 and EED
Fig. 1 PRC2 enzymatic activity is not required for its association to chromatin. a Schematic representation of the CRISPR/Cas9 strategies used to generate
knock-out (KO) and knock-in (KI) mESCs. Scissors indicate the position of the sgRNAs used for Cas9 targeting. bWestern blot analysis using the indicated
antibodies with protein extracts obtained from WT, Ezh1 KO, Ezh2 KO, Ezh1/2 dKO, and Ezh1 KO-Ezh2 Y726D mouse ESC lines. Vinculin and histone
H3 were used as loading controls. c Immunoprecipitations using EZH2 antibody with total protein extracts from the indicated cell lines. Western blots
were performed with the indicated antibodies. d Heatmaps representing spike-in normalized H3K27me3 and normalized SUZ12 ChIP-seq intensities ± 5 kb
around the transcription start sites (TSS) of the Polycomb-bound promoters in the indicated cell lines. Promoters were ranked according to their ChIP-seq
intensities in WT mESCs. Enrichment plots representing the average distribution of H3K27me3 and SUZ12 ± 5 kb around TSS are shown in the upper
panels. Target regions (N= 3968) were selected considering SUZ12 and RING1B peaks with P≥ 1 × 10–1 in wild-type mESCs. e Overlap between the
H3K27me3- and SUZ12-bound promoters in the indicated cell lines. f Representative genomic snapshots for H3K27me3 and SUZ12 ChIP-seq analyses
performed in the indicated cell lines. Regions of H3K27me3 spreading outside the boundaries of SUZ12 chromatin association are highlighted
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levels but also deposition of all forms of H3K27 methylation to
normal (Fig. 3b). Moreover, consistent with results presented in
Fig. 1b, the EZH2 Y731D mutation under these conditions was
unable to recover H3K27 methylation (Fig. 3b). ChIP-seq ana-
lyses in the same cells conﬁrmed these results and further
demonstrated that PRC2 (SUZ12) can be recruited de novo to the
same target sites independently of its ability to deposit
H3K27me3 (Fig. 3c, d and Supplementary Fig. 6).
PRC2 has been shown to have a speciﬁc binding afﬁnity for
H2Aub1 deposited by the PRC1 complex32–34. It is therefore
possible that the ability of PRC2 to be recruited to PcG target sites
in the absence of H3K27me3 could be mediated by the presence
PRC2 peak
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of H2Aub1, which was unchanged in Ezh1/2 dKO and Ezh2
Y726D ESC lines (Figs. 1b and 3b). As inactivation of RING1A/B
activity induces a rapid loss of ESC viability6, we eliminated
H2Aub1 with MG132 treatment, which rapidly reduces the pool
of free ubiquitin in the cell (and thus also H2Aub1 levels)42.
Indeed, after 6 h of MG132 treatment in Ezh2 Y726D ESCs,
H2Aub1 deposition was nearly abolished, but the global levels
of core PRC2 components were not affected (Fig. 4a and
Supplementary Fig. 7A, B). ChIP-seq analysis in these cells
conﬁrmed this result, demonstrating that H2Aub1 deposition
is affected at all genomic sites that are also bound by the
PRC1 complex in WT ESCs (Fig. 4b). Importantly, ChIP-seq
analysis for SUZ12 in the same samples showed correct
binding of the PRC2 complex at a genome-wide level, with no
Fig. 2 PRC2-EZH1 is unable to spread H3K27me3 deposition but preserves target genes repression. a Illustration describing the criteria used to select
SUZ12 inside peak regions, its boundaries, and the regions selected for the analysis at the 5′ and 3′ outside SUZ12 peak boundaries. b Boxplots representing
H3K27me3 density distribution in WT and Ezh2 KO cells within PRC2 peaks, as well as 1.2 kb outside the 5′ and 3′ ends. P-values were determined using a
Student’s t-test. c Left panels, boxplots representing the distribution of the H3K27me3 density ratio between the H3K27me3 density inside PRC2 peaks
(PEAK in a) and at 5′ (left panel) or 3′ (right panels) spreading regions (5′ or 3′ spread in a). P-values were determined using a Student’s t-test. Right
panels, the correlation for the IN/OUT H3K27me3 density ratio between WT and Ezh2 KO cells. The linear correlation coefﬁcient (r) and coefﬁcient of
determination (r2) are shown in the graphs. d Left panels, boxplots representing the distribution of the H3K27me3 density ratio between the H3K27me3
density inside PRC2 peaks (PEAK in a) and at 5′ (left panel) or 3′ (right panels) spreading regions (5′ or 3′ spread in a) considering the top 20%
H3K27me3 enriched promoters in Ezh2 KO cells based on P-values. P-values were determined using a Student’s t-test. Right panels, the correlation for the
IN/OUT H3K27me3 density ratio between WT and Ezh2 KO cells. The linear correlation coefﬁcient (r) and coefﬁcient of determination (r2) are shown in
the graphs. e Volcano plots of differentially expressed genes in the indicated cell lines compared to WT. Log2FC≥ 1
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signs of displacement (Fig. 4b, c). To strengthen this conclusion,
we generated Ezh1/2 dKO in Ring1A KO ESC carrying a
conditional allele for Ring1B (Ring1b ﬂ/ﬂ). We have further
introduced in these cells a tetracycline inducible form of EZH2
to activate ﬁrst, the loss of PRC1 activity by OHT treatment
and second, the activation of EZH2 expression with doxycycline
(doxy; Fig. 4d, e). ChIP analysis at PRC2 targets showed that
also under these experimental conditions, SUZ12 was efﬁciently
recruited at target sites regardless of PRC1 activity (Fig. 4f).
This result was valid also for different PRC2 ancillary subunits
(MTF2, JARID2 and PHF19) with the exception of EPOP, which
seems to be affected in binding upon MG132 treatment
(Supplementary Fig. 7C). Overall, these results suggest that the
PRC2 complex is recruited to speciﬁc loci by intrinsic properties
that are independent of its ability to bind either H3K27me3
or H2Aub1.
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EZH1 activity fully preserves PRC1-mediated repression. Since
loss of EZH2 strongly affected H3K27me2 deposition without
altering H3K27me1 levels in bulk (Fig. 1b), we also proﬁled the
deposition of these two PRC2-dependent modiﬁcations by ChIP-
seq analyses. We stratiﬁed all RefSeq genes in three groups: PcG
targets, non-PcG targets with low H3K36me3 levels and non-PcG
targets with high H3K36me3 deposition (Fig. 5a). Consistent with
Fig. 1b results, Ezh2 KO, Ezh1/2 dKO and Ezh2 Y726D ESC
showed a complete loss of H3K27me2 deposition at the intragenic
regions of poorly expressed genes. However, in Ezh2 KO ESC,
H3K27me2 accumulated at PcG bound promoters compensating
the reduction in H3K27me3 (Fig. 5a). Similarly, H3K27me1
accumulated at poorly transcribed intragenic regions where
H3K27me2 was lost. Unexpectedly, H3K27me1 deposition at
highly transcribed genes was completely lost in Ezh2 KO ESC,
suggesting that EZH2 could be speciﬁcally involved in supporting
this activity (Fig. 5a).
We took advantage of these mutants to further explore the
relationship between PRC1 and PRC2 recruitment. We ﬁrst
analyzed RING1B chromatin association by ChIP-seq analyses in
WT, Ezh2 KO, Ezh1/2 dKO, and Ezh2 Y726D ESCs. As expected,
RING1B was efﬁciently associated to the same repertoire of
genomic loci bound by PRC2 in WT ESCs, conﬁrming that both
complexes co-occupy the vast majority of target sites (Supple-
mentary Figs. 2B, 5B, and 5C). Importantly, RING1B binding was
completely abolished in both Ezh1/2 dKO and Ezh2 Y726D ESCs,
demonstrating that RING1B is recruited to PcG target loci by
H3K27me3 deposition independently of whether or not PRC2 is
associated to the same site (Fig. 5b, c). However, RING1B was not
displaced in Ezh2 KO ESCs retaining an unaltered chromatin
association proﬁle identical to WT ESCs. Consistent with the
good afﬁnity of CBX7 in binding also H3K27me243, these results
showed that the remaining H3K27me3 together with H3K27me2
accumulation is sufﬁcient to preserve efﬁcient PRC1 recruitment
to chromatin at PcG sites in the absence of EZH2 activity.
H3K27ac plays an active role in cell identity control. Consistent
with previous reports39,40, loss of PRC2 activity resulted in a
global increase of H3K27ac levels (Fig. 1b). Although such
increases occur sparsely along the genome as a consequence of
H3K27me2 loss, H3K27ac preferentially accumulates both at
promoters and distal regulatory sites17,44. Focusing on all RefSeq
genes transcription start sites (TSS) in WT ESCs, we observed
that H3K27me3 and H3K27ac were deposited in a mutually
exclusive manner, with PcG target promoters showing unde-
tectable H3K27ac levels, while active promoters showing accu-
mulation (Fig. 6a, b). Upon loss of PRC2 activity (in Ezh1/2
dKOs), the levels of H3K27ac increased globally, invading pro-
moters that were previously decorated by H3K27me3 (Fig. 6a, b).
H3K27ac promoter invasion also occurred in Ezh2 Y726D ESCs,
even though these cells have a catalytically inactive PRC2 that
remained bound at these sites. Importantly, H3K27ac invasion at
these promoters was signiﬁcantly prevented in Ezh2 KO ESC by
residual H3K27me3 deposition and H3K27me2 accumulation
(Fig. 6a, b). Consistent with previous reports45, accumulation of
H3K27ac did not result in differential chromatin accessibility at
both promoters and enhancer sites (Supplementary Fig. 8A–C)
and was not a consequence of a generally increased P300 and
CBP activity (Supplementary Fig. 9A, B). Interestingly, while
acetylation of other lysine residues of the H3 n-terminal tail
was unaffected, some residues of histone H4 also gained acet-
ylation in a PRC2-dependent manner (Supplementary Fig. 9C),
suggesting an unexpected crosstalk. Overall, these results
demonstrated that the major determinant for restricting acetyla-
tion at promoters is the methylated status of H3K27, regardless of
PRC2 chromatin association.
To investigate how distinct chromatin states contribute to
the differentiation capabilities of ESCs, we tested whether the
different mutants could form embryoid bodies (EBs) in cell
culture. Consistent with the complete compensation for all
H3K27 methylation states exerted by EZH2, Ezh1 KO EBs
displayed normal morphology with respect to WT cells (Fig. 7a).
In contrast, Ezh2 KO, Ezh1/2 dKO, and Ezh2 Y726D mutant
ESCs displayed compromised differentiation capabilities (Fig. 7a).
This highlights that maintenance of repressive domains at
target promoters by H3K27me2/3 and PRC1 recruitment is not
sufﬁcient to prevent developmental failure, suggesting a potential
role for diffused chromatin H3K27 hyperacetylation in PRC2
developmental defects. To gain further evidence in this direction,
we generated in an Ezh1 KO background a new EZH2 mutation
(Ezh2 R685C; Supplementary Fig. 10A) that showed a preferential
rescue of H3K27me2 activity respect to H3K27me3 (Fig. 7b).
This resulted in attenuated bulk increase of H3K27ac (Fig. 7b)
respect to Ezh2 KO, with no spreading at PRC2 target promoters
(Fig. 7c). Importantly, Ezh2 R685C EBs showed a morphology
that look more similar to wild-type ESC (Fig. 7a). While all
mutant ESC expressed and downregulated pluripotency markers
when differentiated in EBs (Supplementary Fig. 10B), Ezh2
KO, Ezh1/2 dKO, and Ezh2 Y726D EBs failed to correctly
activate markers of differentiation for different lineages (Fig. 7d).
In contrast, these defects were markedly attenuated in the
Ezh2 R685C EBs in agreement with their normal morphology
(Fig. 7a, d). These results demonstrated that establishment of
H3K27me3/2 deposition at target promoters and maintenance
of PRC1 repressive domains is not sufﬁcient to prevent
developmental failure (Fig. 7a). These data further suggest that
a diffused increase in chromatin H3K27ac could play a direct
role in PRC2-dependent loss of cell identity control.
Discussion
Here, we have demonstrated that, in absence of PRC2-EZH2
activity, PRC2-EZH1 is only able to sustain H3K27me1 deposi-
tion at a global level in vivo. Using more sensitive ChIP-seq
analyses, we discerned that H3K27me3 is nonetheless still
signiﬁcantly deposited at all PRC2 target promoters ( > 70%)
identiﬁed in WT ESCs, and compensated by H3K27me2 (Fig. 5).
Thus, although with a reduced efﬁciency, PRC2-EZH1 retained
the ability to target and modify the same repertoire of target
Fig. 5 EZH1-mediated accumulation of H3K27me2 at promoters sustains maintenance of PRC1 repressive domains. a Heatmaps representing the spike-in
normalized H3K36me3, H3K27me1, H3K27me2, and H3K27me3 ChIP-seq intensities within the entire normalized gene length plus a ± 1 kb region
around all annotated RefSeq genes (N= 31027). Regions were clustered into Polycomb targets, H3K36me3 positive and negative regions. PcG targets were
ranked for the intensity of H3K27me3 deposition while the rest of RefSeq genes for ascending intensity of H3K36me3 in WT cells. Upper boxplots
represent the average normalized intensities of H3K36me3, H3K27me1, H3K27me2, and H3K27me3 in the indicated cell lines in the different gene
clusters. b Representative genomic snapshots of RING1B ChIP-seq analyses performed in the indicated cell lines. c Heatmaps representing the normalized
RING1B and the spike-in normalized H3K27me1, H3K27me2, and H3K27me3 ChIP-seq intensities ± 5 kb around TSS of Polycomb-bound promoters in
the indicated cell lines. Promoters were ranked according to their intensities in WT mESCs. Enrichment plots representing the average distribution of
RING1B, H3K27me1, H3K27me2, and H3K27me3 ± 5 kb around TSS are shown in the upper panels
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09624-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1679 | https://doi.org/10.1038/s41467-019-09624-w |www.nature.com/naturecommunications 9
promoters of PRC2-EZH2 in ESCs. This is in line with the
functional and biochemical proprieties of PRC2-EZH1 and
PRC2-EZH2 shown by several studies. In general, PRC2-EZH2
is primarily linked to cell proliferation, and PRC2-EZH1, to
differentiated post-mitotic conditions19,46. A series of biochem-
ical studies revealed the importance of allosteric stimulation
of PRC2 for the nucleation and spreading of H3K27me3
domains at a genome-wide level, demonstrating its importance
in sustaining H3K27me2/me3 deposition47. Notably, minor
differences in the amino acid sequence of the stimulatory
responsive domain between EZH1 and EZH2 render EZH1 less
responsive to allosteric stimulation than EZH248. Importantly,
PRC2-EZH1-mediated H3K27me2/3 deposition at target genes
was sufﬁcient to preserve PRC1 binding and gene repression
(Figs. 2e and 5b, c).
The mechanisms by which PRC2 is targeted to chromatin play
an important aspect of PRC2 activity regulation. Different bio-
chemical features can stabilize PRC2 recruitment to target sites,
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including its intrinsic afﬁnity for CpG-rich DNA elements29,49,50,
long non-coding RNAs51–53, and ancillary proteins associated to
PRC231. Recent work has further identiﬁed speciﬁc CG-rich
consensuses that seem to serve as nucleation sites for PRC2
recruitment and spreading47. Different forms of PRC2 also have
distinct afﬁnities in binding chromatin templates. For instance,
EZH1 was shown in vitro to bind nucleosome templates with
a greater afﬁnity than EZH248. Moreover, different analyses
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Fig. 7 Diffused accumulation of H3K27ac directly contributes to PRC2-mediated differentiation defects. a Pictures of embryoid bodies at day 7 (d7) of
differentiation, from the indicated ESC lines (shown at ×4 magniﬁcation). b Western blot analysis using the indicated antibodies with protein extracts
obtained from WT, Ezh2 KO, Ezh1/2 dKO, Ezh1 KO-Ezh2 Y726D, and Ezh1 KO-Ezh2 R685C mouse ESC lines. Histone H3 was used as loading control.
c ChIP-qPCR of H3K27ac in the indicated mESC lines. IgG rabbit served as negative control. Enrichments are normalized to % INPUT. Data are represented
as mean ± SEM. d Heatmaps of qPCR relative expression analyses for the indicated genes at d0, d5, d7, and d9 during ESC differentiation of the cells
indicated shown in a. Gapdh expression served as a normalization control
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studying the function of ancillary proteins, such as MTF2,
JARID2, and AEBP2, have shown that all of these activities
contribute to stabilizing PRC2 at chromatin and to stimulating
its in vitro activity23,34,54. In particular, JARID2 can be methy-
lated by EZH2 on K116, resulting in allosteric stimulation with
the same mechanism as for H3K27me355. While JARID2 plays
a crucial role in the context of ESCs, its function in more-
committed cell types is marginal, suggesting that different
mechanisms for stimulatory actions and recruitment exist. Recent
work from the Helin laboratory has further shown that a form of
SUZ12 unable to associate with PRC2 is still recruited to PcG
target sites41. Our results in Ezh1/2 dKO ESC also show that
SUZ12 binding is retained at PcG sites, however with lower
intensity respect to wild-type ESC. The catalytically inactive form
of PRC2 supports this notion, showing that PRC2 can associate
to all its target sites at a genome-wide level in the absence of
any form of H3K27 methylation (Fig. 1). In these conditions,
SUZ12 binding was stabilized respect to Ezh1/2 dKO cells,
suggesting SUZ12 assembly into a PRC2 complex favors its
chromatin association independently of PRC2 catalytic activity.
How PRC2 acquires speciﬁcity for target gene recognition in
speciﬁc cell lines is also an important open question. Here, we
showed that in ESCs that had been cultured for an indeﬁnite
number of passages in the absence of any form of PRC2 activity
(Ezh1/2 dKO), H3K27me3 deposition and PRC2 target associa-
tion were fully restored within 24 h after EZH2 re-expression
(Fig. 3) conﬁrming that speciﬁcity remains an intrinsic feature of
cellular identity. PRC2 is attracted to CpG-rich DNA elements49,
an afﬁnity linked to MTF2 DNA binding proprieties26, and to
speciﬁc motifs within CpG islands (CpGi) that were linked
to PRC2 de novo nucleation47. The lack of transcription from
CpG-rich promoters was further proposed as a determinant for
PRC2 recruitment, which would imply that all CpGi are potential
targets of PRC230. Importantly, our catalytically inactive EZH2
mutant was recruited to all PRC2 target sites, despite its inability
to deposit any form of H3K27 methylation. Although in agree-
ment with the H3K27me3 nucleation and spreading model47,
this result further suggests that de novo binding of PRC2 to all
target sites is uncoupled from H3K27me3 nucleation. Overall,
our data link the models of PRC2 being tethered by transcrip-
tional silencing with the mechanisms of spreading H3K27me3
domains.
PRC2 was also shown to retain biochemical afﬁnities for
H2Aub, which is deposited by PRC1 activity. Further, loss of
RING1A/B activity can affect the association of PRC2 at target
sites in ESCs, suggesting that H2Aub1 is a determinant for spe-
cifying PRC2 target association32–34. However, in Ezh2 Y726D
ESCs, H2Aub1 levels were not affected either at bulk levels
(Fig. 1b) or in genome-wide deposition (Fig. 4b). This suggests
that retained H2Aub1 deposition could serve as a docking site for
de novo PRC2 recruitment and H3K27me3 deposition, thus
deﬁning genome-wide binding speciﬁcity. Our results now clearly
show that acute depletion of H2Aub1 neither results in release of
PRC2 nor affects PRC2 ability to be re-recruited at is target loci,
regardless of the presence of any form of H3K27 methylation
(Fig. 4). Based on this result, we would suggest that PRC2 binding
afﬁnity for H2Aub1 serves more to reinforce already-formed PcG
repressive domains than to deﬁne de novo sites.
Our data further revealed that PRC2-EZH1 was still able to
deposit H3K27me3 at virtually all PRC2 target sites that we
classiﬁed in WT ESCs. A careful analysis of this activity in Ezh2
KO ESCs highlighted that H3K27me3 deposited by EZH1 was
conﬁned within the boundaries of the association of PRC2 with
chromatin and was unable to spread outside these regions
(Fig. 2). This suggests that an inefﬁcient allosteric stimulation
previously measured in vitro for PRC2-EZH148 is likely to
conﬁne H3K27me3 deposition within the boundaries of PRC2
physical association with chromatin. Nevertheless, within these
boundaries, PRC2-EZH1 was able to deposit H3K27me3 at
levels comparable to those in WT ESCs (Fig. 2), further accu-
mulating H3K27me2 (Fig. 5a). Interestingly, EZH1 accumulated
H3K27me2 at these sites but failed to normally deposit
H3K27me1 at transcribed genes, suggesting speciﬁc contributions
of the two methyltransferases in deﬁning the H3K27 methylation
landscape. Overall, our data as well as those from others41,47,48,56
demonstrate that PRC2 recruitment is uncoupled from the
mechanism by which H3K27me3 repressive domains are formed,
highlighting the importance of allosteric EZH2 stimulation for
spreading but not for deposition of H3K27me3 at all PcG
target sites.
In Drosophila melanogaster, PcG proteins are recruited to
target sites via the recognition by the DNA binding transcription
factors of DNA elements, named PREs, which can be located at
considerable distances from target promoters27. This results in
the establishment of very large H3K27me3 domains with respect
to what is observed in mammalian genomes57. This may suggest
that repressive mechanisms have diverged to adapt to the
changes in the evolution of distinct genomic features. Work of the
Muller laboratory has demonstrated that fully penetrant H3K27
amino acid substitutions can phenocopy the homeotic transfor-
mations observed for PRC2 mutants during ﬂy development37.
This points at H3K27me3 as an essential executor of develop-
mental functions, but whether this is true also for mammals
remained unclear. Taking advantage of our catalytically inactive
PRC2 mutant ESCs, we have now demonstrated that the absence
of H3K27 methylation, but not of PRC2 association to target
promoters per se, phenocopied the developmental defects
observed in Ezh1/2 dKO developing EBs (Fig. 7). This demon-
strates that deposition of H3K27 methylations, but not PRC2
recruitment to target sites, is an essential feature for at least
early developmental decisions.
It is important to highlight that developmental defects very
similar to those in catalytically inactive PRC2 mutant ESC lines
were also observed in Ezh2 KOs but not in Ezh1 KOs. The lack of
such defects in Ezh1 KOs further conﬁrms the essential role of
H3K27 methylation, as EZH2 fully compensated loss of EZH1
activity (Fig. 1). In contrast, the defects observed for Ezh2 KOs
highlights that an altered deposition of H3K27 methylated
forms is critical in early developmental decisions. Both results
are in complete agreement with the lack of developmental defects
previously observed in Ezh1 KO mice20 and with the early
embryonic lethality reported for Ezh2 KO embryos during gas-
trulation stages2. These developmental defects were phenocopied
by complete loss of PRC2 activity in Eed or Suz12 KO embryos3,4.
One critical activity of PRC2 is its ability to affect PRC1
recruitment to chromatin. PRC1 can exist in different forms that
can be roughly divided in canonical and non-canonical forms.
Canonical PRC1 complexes are characterized by the presence
of CBX proteins, which retain binding afﬁnities for H3K27me3
substrates31. Our results clearly demonstrate that RING1B was
severely displaced in the absence of H3K27me3 deposition at
target sites, regardless of the presence or absence of PRC2
at target promoters (Ezh1/2 dKO vs. Ezh2 Y726D). This accounts
for approximately 90% of total RING1B associated at PcG sites
in agreement with previous reports using Eed KO ESCs58.
The massive RING1B displacement (Fig. 5b, c) further suggests
that canonical PRC1 remains the predominant form active in
ESCs and that its chromatin displacement cannot be fully com-
pensated by additional recruitment of non-canonical forms.
Our data further demonstrated that RING1B binding was fully
retained at target sites in the absence of PRC2-EZH2 activity,
likely by the localized deposition of H3K27me3 and accumulation
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of H3K27me2 by PRC2-EZH1 (Fig. 5). Indeed, CBX7 still retains
a signiﬁcant afﬁnity in binding H3K27me2 respect to H3K27me3
(Kd: ~ 136 vs. ~ 22 µM µM, respectively43). Importantly, while
H3K27me2/3 deposition and PRC1 association at target sites
were sufﬁcient to maintain target genes repression, they were
not sufﬁcient to prevent developmental failure when Ezh2 KO
ESCs were challenged to differentiate into EBs. This suggests that
additional features to the direct control of target genes repression
could contribute to proper development. Our data using the
Ezh2 R685C mutant further suggest that diffused chromatin
H3K27ac could be a major determinant in PRC2-mediated
developmental defects.
We have previously shown that the distinct forms of H3K27
methylation are spatially organized along the genome.
H3K27me2 is broadly diffused and modiﬁes >70% of histone
H3 present in ESCs17. In addition, we and others have shown that
loss of PRC2 enzymatic activity always results in an aberrant
increase in the levels of H3K27 acetylation39,40. We have pre-
viously mapped the sites of H3K27ac accumulation in Eed KO
ESCs and have shown that such deposition occurs at both
H3K27me3-decorated promoters and in the intra- and intergenic
space at which H3K27me2 is broadly diffused17. As this can
result in an altered activation of enhancer elements, we speculate
that loss of H3K27me2 deposition could have a major role in
PRC2-dependent deregulated control of cell identity. Although
Ezh2 KO ESCs showed a similar gain in H3K27ac as Ezh1/2 dKO
and Ezh2 Y726D ESCs, our ChIP-seq analyses for H3K27ac in
Ezh2 KOs demonstrated that all PcG target promoters were
more protected from H3K27 hyperacetylation (Fig. 6). This
suggests that in the absence of EZH2 activity, PcG target pro-
moters remain protected by the presence of local H3K27me3
deposition, accumulation of H3K27me2 and maintenance of
PRC1 binding. This may link diffused H3K27 hyperacetylation
with developmental failure. Indeed, this is further supported by
the attenuated differentiation defects observed in the Ezh2 R685C
mutant, which correlate with their reduced accumulation of
H3K27ac.
Overall, our results provide evidences to suggest that diffused
chromatin hyperacetylation could directly contribute to the early
developmental defects observed in PRC2 defective ESCs. In
agreement with previous reports, our data show that this does not
involve genome-wide changes in chromatin accessible sites.
Whether this involves a speciﬁc unbalance in enhancer activity
or a more global effect on chromatin three-dimensional con-
formation are interesting open questions to pursue. In light of
the speciﬁc roles that PRC1 and PRC2 play in distinct adult
tissues20,59–63, it will now also be very important to understand
the contributions of diffuse H3K27 hyperacetylation in the
homeostasis of organs and tissues. Increased H3K27 acetylation
in DIPG pediatric brain tumors, in which PRC2 activity is
inhibited by the expression of a H3K27M mutation, renders
tumors cells more sensitive to BET inhibitors64. Therefore, con-
sidering the frequent gain- and loss-of-function mutations that
affect different PRC2 subunits, it will be important to explore
the contributions of these mechanistic aspects in different
pathological contexts.
Methods
Cell lines and cell culture. ESCs KO clones were generated in E14TG2a by
CRISPR/Cas9 targeting Ezh1 or Ezh2 genes using double sgRNAs to excise the
whole gene of interest. Clones were screened by PCR followed by Sanger
sequencing to conﬁrm the macrodeletions. Ezh2 Y726D and Ezh2 R685C ESCs
were obtained by precise editing using a speciﬁc single-stranded template (ssODN,
IDT) in Ezh1 KO cells. Introduction of the desired point mutation was conﬁrmed
by restriction analysis followed by Sanger sequencing.
mESCs were grown on 0.1% gelatin-coated dishes in 2i/LIF-containing GMEM
medium (Euroclone) supplemented with 20% fetal calf serum (Euroclone), 2 mM
glutamine (Gibco), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco), 0.1 mM
non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 50 µM ß-
mercaptoethanol phosphate-buffered saline (PBS; Gibco), 1000 U/ml leukemia
inhibitory factor (LIF; produced in-house), and GSK3β and MEK 1/2 inhibitors
(ABCR GmbH) to a ﬁnal concentration of 3 μM and 1 μM, respectively.
Rosa26:Cre-ERT2 Ring1A KO Ring1B ﬂ/ﬂ conditional mESC and Ring1b KO
mESC lines were generated elsewhere6,9. Ring1A-/-; Ring1B ﬂ/ﬂ;Rosa26::CreERT2
conditional mESC were subjected to CRISPR/Cas9 editing in order to obtain
double Ezh1/Ezh2 KO. Cells were transduced with 5 μg/ml polybrene and lentiviral
particles delivering pLIX_402 vector (Addgene #41394) expressing human wild-
type EZH2 for 36 h and then subjected to 72 h -long puromycin-selection (1 μg/
ml). For inducible EZH2 re-expression, cells were treated for 24 h with 0.5 μM
4-hydroxytamoxifen (4-OHT; or EtOH as control) in order to obtain Ring1b KO;
then were treated with a combination of 4-OHT (or EtOH) and doxycycline
(1 μg/ml) for 48 h prior harvesting.
mESCs were induced to differentiate to EBs by LIF removal in hanging drops
(1000 cells/20 μl drop) on the lid of 15 cm petri dishes for 48 h. EBs were then
collected and stimulated with 0.5 µM all-trans retinoic acid (ATRA) for 3 days. EBs
were left in culture in non-coated petri dishes in ES medium without LIF until
day 7. Medium was replaced every second day.
Where indicated, undifferentiated mESCs were treated with 10 μM MG132
(Calbiochem Merck) dissolved in 100% DMSO for 6 h.
Transfections. For rescue experiments, pCAG vectors encoding Flag-Avi-tagged
human wild-type EZH2 or EZH2 Y731D mutant or pCAG vector encoding
Flag-HA-tagged human wild-type EZH1 were transfected into mESCs using
Lipofectamine 2000 (ThermoFisher Scientiﬁc), according to the manufacturer’s
instructions. Cells were subjected to puromycin selection (2 µg/ml) for 24 h and
then collected for subsequent analyses.
Western blot. For western blot analysis, mESCs were lysed and sonicated in
ice-cold S300 buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 10% glycerol,
0.2% NP-40) and supplemented with protease inhibitors (Roche). For co-
immunoprecipitation experiments, cells were lysed in the same lysis buffer.
Immunoprecipitation was performed on 1mg protein extracts using homemade
anti-EZH2 (AC22) cross-linked sepharose beads (30 μl slurry for IP, Healthcare,
cat. # 170780-01) for 3 to 4 h at 4 °C. Immunocomplexes were washed 5× with S300
buffer and eluted in Laemmli sample buffer. Protein lysates were separated on
sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to
nitrocellulose membranes. After probing with the suitable primary and secondary
antibodies, chemoluminescence signals were captured with the ChemiDoc Imaging
System (Bio-Rad).
Antibodies. Western blot analyses were performed with: anti-Vinculin (1:8000
dilution; V9131; Sigma-Aldrich), anti-Oct3/4 (1:1000 dilution; sc5279; Santa
Cruz Biotechnology), anti-Ezh2 (1:10 dilution; BD43 clone; homemade3), anti-
Suz12 (1:1000 dilution; sc-46264; Santa Cruz Biotechnology), anti-Eed (1:10
dilution; AA19 clone; homemade65), anti-p53 (1:5 dilution: homemade), anti-
ﬂag (1:1000 dilution; F3165; Sigma-Aldrich), anti-Mtf2 (1:1000 dilution; 16208-
1-AP; Proteintech), anti-Jarid2 (1:1000 dilution; ab48137; Abcam), anti-Phf19
(1:1000 dilution; 11895-1-AP; Proteintech), anti-EPOP (1:1000 dilution)66, anti-
P300 (1:500 dilution; sc-585; Santa Cruz Biotechnology), anti-CBP (1:200 dilution;
sc-583; Santa Cruz Biotechnology), anti-HA (1:10 dilution; 12CA5 clone; home-
made), anti-H3K27me1 (1:1000 dilution; 61015; Active Motif), anti-H3K27me2
(1:1000 dilution; 9728; Cell Signaling Technology), anti-H3K27me3 (1:1000
dilution; 9733; Cell Signaling Technology), anti-H3K27ac (1:1000 dilution; ab4729;
Abcam), anti-H3K9K14ac (1:1000 dilution; C15410200; Diagenode), anti-H3K14ac
(1:500 dilution; 39599; Active Motif), anti-H3K18ac (1:500 dilution; E-AB-20285;
Microtech), anti-H3K23ac (1:500 dilution; E-AB-20205; Microtech), anti-H4K5ac
(1:1000 dilution; 39170; Active Motif), anti-H4K8ac (1:500 dilution; E-AB-20208;
Microtech), anti-H4K12ac (1:500 dilution; 39166; Active Motif), anti-H4 (1:1000
dilution; ab7311; Abcam), anti-H2AK119ub (1:1000 dilution; 8240; Cell Signaling
Technology), anti-H3 (1:8000 dilution; 1791; Abcam), and anti-H2A (1:1000
dilution; 12349; Cell Signaling Technology).
ChIP assays were performed using: anti-Suz12 (3737; Cell Signaling
Technology), anti-Ring1b (homemade;63), anti-HA (12CA5 clone; homemade),
anti-Jarid2 (ab48137; Abcam), anti-Mtf2 (16208-1-AP; Proteintech), anti-Phf1967,
anti-EPOP66, anti-H3K27me1 (61015; Active Motif), anti-H3K27me2 (9728; Cell
Signaling Technology, anti-H3K27me3 (9733; Cell Signaling Technology), anti-
H3K27ac (ab4729; Abcam), anti-H3K36me3 (4909; Cell Signaling Technology),
anti-H2AK119ub (8240; Cell Signaling Technology) and puriﬁed rabbit IgG
(I5006; Sigma-Aldrich).
Quantitative real-time PCR (qPCR). Total RNA was extracted with the Quick-
RNA™ MiniPrep extraction kit (Zymo Research) and retro-transcribed with
ImProm-II™ Reverse Transcription System (Promega) according to the manu-
facturer’s instructions. Quantitative real-time PCR (qPCR) was carried out using
GoTaq qPCR master mix (Promega) on CFX96 Real-Time PCR Detection System
(Bio-Rad). Gapdh was used as a control gene for normalization.
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Graphical representations of qPCR analysis were generated in R by function
“pheatmap”. Primer sequences are available upon request.
RNA-seq. RNA-seq was performed following SMART-seq2 protocol68 with minor
modiﬁcations. Brieﬂy, poly-A containing mRNA molecules obtained from 1 μg
of total RNA were copied into ﬁrst-strand cDNA by reverse transcription and
template-switching using oligo(dT) primers and an LNA-containing template-
switching oligo (TSO). Resulting cDNA was pre-ampliﬁed with KAPA HotStart
Taq enzyme (Kapa Biosystems) and then puriﬁed with Ampure beads (Agencourt
AMPure XP- Beckman Coulter). Two nanograms of pre-ampliﬁed cDNA were
tagmented with in-house produced Tn5 transposase and further ampliﬁed with
KAPA HotStart Taq enzyme. After puriﬁcation with Ampure beads, the quality of
the obtained library was assessed by Bioanalyzer (High Sensitivity DNA kit, Agilent
Technologies), prior sequencing.
RNA-seq analysis. Reads were aligned to the mouse reference genome mm9 using
TopHat v2.1.169. Duplicates were removed using PICARD (http://broadinstitute.
github.io/picard/). HTseq-count v0.8.070 was used to calculate counts with para-
meters --stranded= no --mode= intersection-nonempty using RefSeq mm9
annotation downloaded from UCSC. DESeq2 v1.20 R package was used to perform
differential expression analyses using default parameters71. Genes with an absolute
log2 fold change of 1 were considered as differentially expressed.
Chromatin immunoprecipitation (ChIP). ChIP experiments were performed
according to standard protocols7. Brieﬂy, 1% formaldehyde cross-linked chromatin
was sheared to 500–1000 bp fragments by sonication and incubated overnight in IP
buffer (33 mM Tris-HCl pH 8, 100 mM NaCl, 5 mM EDTA, 0.2% NaN3, 0.33%
SDS, 1.66% Triton X-100) at 4 °C with the indicated antibodies. For ChIP for
SUZ12 and RING1B, 400–500 μg of chromatin and 5 μg of antibodies were used.
For ChIP for histone modiﬁcations, 200–250 μg of chromatin supplemented with
5% spike-in of S2 Drosophila chromatin (prepared in the same manner) and 3 μg
of antibodies were used. The next day, chromatin lysates were incubated for 2 to 4
h with protein-A sepharose beads (GE Healthcare). Beads were washed 3× with
low-salt buffer (150 mM NaCl, 20 mM Tris-HCl pH 8, 2 mM EDTA, 0.1% SDS, 1
% Triton X-100) and 1× with high-salt buffer (500 mM NaCl, 20 mM Tris-HCl pH
8, 2 mM EDTA, 0.1% SDS, 1% Triton X-100), and then re-suspended in de-
crosslinking solution (0.1 M NaHCO3, 1% SDS). DNA was puriﬁed with QIAquick
PCR puriﬁcation kit (Qiagen) according to the manufacturer’s instructions. DNA
libraries were prepared with 2–10 ng of DNA using an in-house protocol72 by the
IEO genomic facility and sequenced on an Illumina HiSeq 2000.
ChIP-seq data analysis. Sequencing reads were aligned to the mouse reference
genome (mm9) using Bowtie73, favoring only unique alignments and ﬁltering out
duplicates. For ChIP-RX experiments, sequencing reads were also aligned to the
Drosophila reference genome (dm6) and used to compute a normalization factor
for individual datasets. Peak calling was performed from aligned reads using
MACS274. Signiﬁcant bound regions were deﬁned using a cut-off of p= 1 × 10–1.
BigWig ﬁles were built from Bam ﬁles with 200 bp reads, extension, input sub-
traction, and library size scaling using the function bamCompare from deepTools
2.075. For ChIP-Rx samples the scaling factor was calculated as described in ref. 76.
Heatmaps were generated using the computeMatrix and plotHeatmap utilities
from deepTools75. The matrix was normalized by a factor calculated as 1/(max –
min) when samples were subjected to ChIP analysis with the same antibody. The
reference point for plotting was selected with respect to the transcription start site
(TSS), and the 5000 bp distances upstream and downstream of TSS (TSS ± 5 kb)
were graphically represented. Tracks were subsequently visualized using the IGB
genome browser77.
Boxplots were generated with the package ‘ggplot’’ of R. H3K27me3 density
distribution was computed within SUZ12 peaks and within a 1.2 kb region of 5′
and 3′ of SUZ12 peak boundaries. Target regions (N= 3968) were selected
considering SUZ12 peaks colocalizing with RING1B with P ≥ 1 × 10–1 in wild-type
mESCs. Correlation analysis was performed between wild-type and Ezh2 KO
samples. The IN/OUT density ratio was plotted, and linear regression analysis was
calculated in R. T-test statistics were applied.
ATAC-Seq. ATAC-seq was performed following previous methods78 with minor
modiﬁcations. Brieﬂy, 50,000 mESCs were directly lysed (lysis buffer: 10 mM Tris-
HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% NP-40), re-suspended in 50 μl
of TAPS-buffer 1 × (TAPS 5x buffer: 50 mM TAPS-buffer, pH 8.3 and 25 mM
MgCl2) added with 8% PEG and in-house produced Tn5 transposase and incu-
bated at 37 °C for 1 h at slow agiting (500 rpm). After a double puriﬁcation with
Ampure beads (Agencourt AMPure XP- Beckman Coulter) recovered tagmented
DNA was ampliﬁed and barcoded by PCR performed with KAPA HotStart Taq
enzyme (Kapa Biosystems).
After size selection step with Ampure beads, libraries were eluted in 22 μl of
pure water, quantiﬁed with Qubit ﬂuorometer (Invitrogen) and checked with
Bioanalyzer instrument (High Sensitivity DNA kit, Agilent Technologies), prior
sequencing.
ATAC-seq data analysis. Paired sequencing reads were aligned to the mouse
reference genome (mm9) using Bowtie v1.2.273, favoring only unique alignments
and ﬁltering out duplicates with PICARD. Heatmaps were generated using the
computeMatrix and plotHeatmap utilities from deepTools75. Boxplot of normal-
ized intensity was performed with ggplot. Enhancers annotation was obtained from
previous work in ESC79.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data supporting the key ﬁndings of this study are available within the article
and its Supplementary Information ﬁles or from the corresponding author upon
reasonable request. All ChIP-seq, RNA-seq, and ATAC-seq datasets are available at GEO
under the accession number GSE116603. A source data ﬁle is provided as a
Supplementary Dataset. A reporting summary for this Article is available as a
Supplementary Information ﬁle.
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